Oct, 24 2020 Gilead Lifesciences Inc.'s Veklury (Remdesivir) has become the first treatment for COVID-19 to receive the U.S. Food and Drug Administration approval. The drug is approved for use in adult and pediatric patients 12 years of age and older…


July 6, 2020 Gilead Sciences has announced that the European Commission has granted conditional marketing authorization for Veklury® (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. The conditional marketing authorization was granted in the interest of public…
Recent Post
- CDSCO Introduces Online Process for Additional Variant Applications in Cosmetics
- India Imposes National Ban on Nimesulide for Veterinary Use Due to Toxicity Risks
- Major Relief for MSME Pharma Manufacturers: MoHFW Extends Deadline for Revised GMP Compliance
- Pharmacovigilance system compliance in India
- Simplifying Clinical Trial Amendment Approvals in India